Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Elife|August 17, 2022
The proportion of randomized controlled trials that inform clinical practiceNora Hutchinson, Hannah Moyer, Deborah A Zarin, et al.JAMA|May 20, 2024
Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-AnalysisRenata Iskander, Hannah Moyer, Karine Vigneault, et al.Annals of Internal Medicine|April 29, 2024
The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysisRenata Iskander, Hannah Moyer, Dean Fergusson, et al.JCO Oncology Practice|October 1, 2024
Time Burdens for Participants With Advanced Cancer in Phase I Trials: A Cross-Sectional StudyRenata Iskander, Adele Magnan Robart, Hannah Moyer, et al.Journal of Clinical Epidemiology|January 21, 2026
Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trialsAngela Nelson, Hannah Moyer, Karine Vigneault, et al.Neurology|June 4, 2024
Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug DevelopmentHannah Moyer, Robyn Mellett, Karine Vigneault, et al.Plos One|February 15, 2022
Relationship between lay and expert perceptions of COVID-19 vaccine development timelines in Canada and USAPatrick Bodilly Kane, Hannah Moyer, Amanda MacPherson, et al.Journal of Clinical Epidemiology|April 7, 2023
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trialsHannah Moyer, Merlin Bittlinger, Angela Nelson, et al.Pageof 1